SVRA Share Price Performance
US$5.27
2.26 (75.08%)
Price US$5.27
Share Pricen/a
No trending discussion available.
No recently updated narratives available.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.